‘Global Inflammatory Bowel Diseases Drug Market Worth $9.5bn In 2020’ Says Visiongain Report

22 August 2018
Pharma

Visiongain’s new report Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis indicates that the global Inflammatory Bowel Diseases drug market will see $9.5bn in spending in 2020.

The global inflammatory bowel diseases (IBD) drug market is estimated at $8.5bn in 2016 and $9.5bn in 2020. Biologic therapies are expected to be the main drivers of growth in the world IBD drug market over the forecast period. In 2016, the biologics submarket generated revenues of $5.8bn, accounting for 68% of the global IBD drug market.

The lead analyst of the report said: “The worldwide inflammatory bowel drug market will show moderate sales growth over the next four years from 2016. Patent expiries for Humira and Remicade during our forecast period will bring the market value significantly lower. New drugs entering the market are not expected to be able to offset this loss.

The increased use of biologics will be the main sales driver to 2027. Aminosalicylates, however, will remain an important option for patients, especially those in poor countries, as the cost advantage of aminosalicylates will be more pronounced in those regions.”

The 200-page report contains 89 tables and 50 figures that add visual analysis in order to explain the developing trends within the Global Inflammatory Bowel Diseases drug market. Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Biologics, Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators.

Our study forecasts individual revenues of 17 leading IBD drugs, including these drugs: Humira, Remicade, Asacol, Pentasa, Lialda, Tysabri.
This report also discusses research and development, including drug candidates in these classes: Interleukin (IL) inhibitors, Cell-adhesion molecule (CAM) inhibitors, TNF-alpha inhibitors, Stem cell therapies, JAK inhibitors and Toll-like receptor agonists.

The 200-page report offers market forecasts and analysis for 11 leading national markets and the rest of the world market. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the inflammatory bowel diseases drug market.

The Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis report will be of value to anyone who wants to better understand the Global Inflammatory Bowel Diseases drug market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of Global Inflammatory Bowel Diseases drug market and industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever